RS20050616A - Pyrazoles and methods of making and using the same - Google Patents

Pyrazoles and methods of making and using the same

Info

Publication number
RS20050616A
RS20050616A YUP-2005/0616A YUP20050616A RS20050616A RS 20050616 A RS20050616 A RS 20050616A YU P20050616 A YUP20050616 A YU P20050616A RS 20050616 A RS20050616 A RS 20050616A
Authority
RS
Serbia
Prior art keywords
pyrazoles
making
methods
same
alk
Prior art date
Application number
YUP-2005/0616A
Other languages
English (en)
Inventor
Wen Cherng Lee
Lihong Sun
Feng Shan
Claudio Chuaqui
Mark Cornebise
Timothy Pontz
Marybeth Carter
Juswinder Singh
Sjodin Paula Ann Boriack
Leona Ling
Russell Petter
Original Assignee
Biogen Idec Ma Inc.,
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biogen Idec Ma Inc., filed Critical Biogen Idec Ma Inc.,
Publication of RS20050616A publication Critical patent/RS20050616A/sr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Dermatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Communicable Diseases (AREA)
  • Cardiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Predmetni pronalazak se zasniva na otkriću da jedinejnja formule i poseduju neočekivano visok afinitet za Alk 5i/ili Alk 4 i da mogu biti od koristi kao njihovi antagonisti pri sprečavanju nastnka i/ili pri tretiranju brojnih oboljenja, uključujući fibrotične poremećaje. U jednom rešenju, predmetni pronalazak obezbeđuje jedinejnje formule I (I).
YUP-2005/0616A 2003-02-12 2004-02-12 Pyrazoles and methods of making and using the same RS20050616A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US44677703P 2003-02-12 2003-02-12
PCT/US2004/004049 WO2004072033A2 (en) 2003-02-12 2004-02-12 Pyrazoles and methods of making and using the same

Publications (1)

Publication Number Publication Date
RS20050616A true RS20050616A (en) 2007-09-21

Family

ID=32869552

Family Applications (1)

Application Number Title Priority Date Filing Date
YUP-2005/0616A RS20050616A (en) 2003-02-12 2004-02-12 Pyrazoles and methods of making and using the same

Country Status (21)

Country Link
US (1) US20060264440A1 (sr)
EP (1) EP1596656A4 (sr)
JP (1) JP2006517592A (sr)
KR (1) KR20050101547A (sr)
CN (1) CN1770980A (sr)
AR (1) AR043184A1 (sr)
AU (1) AU2004210855A1 (sr)
BR (1) BRPI0407454A (sr)
CA (1) CA2514382A1 (sr)
CL (1) CL2004000234A1 (sr)
EA (1) EA010161B1 (sr)
GE (1) GEP20084391B (sr)
IS (1) IS7966A (sr)
MX (1) MXPA05008524A (sr)
NO (1) NO20054200L (sr)
NZ (1) NZ542289A (sr)
PL (1) PL378072A1 (sr)
RS (1) RS20050616A (sr)
UA (1) UA82223C2 (sr)
WO (1) WO2004072033A2 (sr)
ZA (1) ZA200506408B (sr)

Families Citing this family (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0313915D0 (en) * 2003-06-16 2003-07-23 Smithkline Beecham Corp Compounds
CA2564175A1 (en) * 2004-04-28 2005-11-10 Arrow Therapeutics Limited Chemical compounds
WO2006019965A2 (en) * 2004-07-16 2006-02-23 Takeda San Diego, Inc. Dipeptidyl peptidase inhibitors
EP1786803A1 (en) * 2004-08-31 2007-05-23 Biogen Idec MA, Inc. Pyrimidinylpyrazoles as tgf-beta inhibitors
EP1798229A4 (en) * 2004-09-07 2009-07-29 Sankyo Co SUBSTITUTED BIPHENYL DERIVATIVE
AU2005295734A1 (en) * 2004-10-15 2006-04-27 Biogen Idec Ma Inc. Methods of treating vascular injuries
TW200639163A (en) 2005-02-04 2006-11-16 Genentech Inc RAF inhibitor compounds and methods
EA015252B1 (ru) 2005-05-10 2011-06-30 Интермьюн, Инк. Способ модуляции стресс-активированной протеинкиназной системы
GB0520475D0 (en) * 2005-10-07 2005-11-16 Arrow Therapeutics Ltd Chemical compounds
EP1981876B1 (en) * 2006-01-11 2011-05-04 Arrow Therapeutics Limited Triazoloanilinopyrimidine derivatives for use as antiviral agents
JP2009530342A (ja) 2006-03-20 2009-08-27 エフ．ホフマン−ラ ロシュ アーゲー Ｂｔｋおよびｓｙｋ蛋白キナーゼを阻害する方法
CN101062916B (zh) * 2006-04-29 2012-12-26 中国人民解放军军事医学科学院毒物药物研究所 三取代1h-吡唑化合物、其制备方法、药物组合物及其制药用途
US8673929B2 (en) * 2006-07-20 2014-03-18 Gilead Sciences, Inc. 4,6-di- and 2,4,6-trisubstituted quinazoline derivatives and pharmaceutical compositions useful for treating viral infections
US9259426B2 (en) 2006-07-20 2016-02-16 Gilead Sciences, Inc. 4,6-di- and 2,4,6-trisubstituted quinazoline derivatives useful for treating viral infections
MX2009000864A (es) 2006-07-28 2009-02-03 Novartis Ag Quinazolinas 2,4-sustituidas como inhibidores de cinasa de lipido.
EP2083863B1 (en) 2006-10-03 2015-03-18 Genzyme Corporation Antibodies to tgf-beta for use in the treatment of infants at risk of developing bronchopulmonary dysplasia
EP2074128B1 (en) * 2006-10-16 2013-08-14 Medicis Pharmaceutical Corporation Therapeutic pyrazolyl thienopyridines
JP5507045B2 (ja) 2006-12-15 2014-05-28 石原産業株式会社 アントラニルアミド系化合物の製造方法
WO2009009059A1 (en) * 2007-07-09 2009-01-15 Biogen Idec Ma Inc. Spiro compounds as antagonists of tgf-beta
BRPI0815042A2 (pt) * 2007-08-01 2015-02-10 Pfizer Compostos de pirazol
CL2009000904A1 (es) 2008-04-21 2010-04-30 Shionogi & Co Compuestos derivados de ciclohexil sulfonamidas que tienen actividad antagonista en el receptor npy y5, composicion farmaceutica y formulacion farmaceutica que los comprende.
CN102099036B (zh) 2008-06-03 2015-05-27 英特芒尼公司 用于治疗炎性疾患和纤维化疾患的化合物和方法
EP3070077B1 (en) 2009-10-06 2018-11-28 Millennium Pharmaceuticals, Inc. Heterocyclic compounds useful as pdk1 inhibitors
JP5857972B2 (ja) * 2010-12-01 2016-02-10 日産化学工業株式会社 多発性骨髄腫の治療効果を有するピラゾール化合物
KR101084729B1 (ko) 2011-06-10 2011-11-22 재단법인 한국원자력의학원 이소옥사졸 유도체를 포함하는 ＴＧＦ-β 활성 저해용 조성물
WO2013014262A1 (en) 2011-07-27 2013-01-31 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for diagnosing and treating myhre syndrome
WO2013062544A1 (en) 2011-10-26 2013-05-02 Seattle Children's Research Institute Cysteamine in the treatment of fibrotic disease
US8889730B2 (en) 2012-04-10 2014-11-18 Pfizer Inc. Indole and indazole compounds that activate AMPK
KR20150020228A (ko) * 2012-05-31 2015-02-25 에프. 호프만-라 로슈 아게 아미노퀴나졸린 및 피리도피리미딘 유도체
EP2877466B1 (en) * 2012-07-26 2016-07-06 F. Hoffmann-La Roche AG Benzisoxazole modulators of neurogenesis
AR092742A1 (es) * 2012-10-02 2015-04-29 Intermune Inc Piridinonas antifibroticas
CA2905242C (en) 2013-03-15 2016-11-29 Pfizer Inc. Indole compounds that activate ampk
CN110452216B (zh) 2014-04-02 2022-08-26 英特穆恩公司 抗纤维化吡啶酮类
PT3321265T (pt) 2015-03-04 2020-07-07 Gilead Sciences Inc Compostos 4,6-diamino-pirido[3,2-d]pirimidina compounds e a sua utilização como moduladores de receptores do tipo toll
US10822337B2 (en) 2015-04-01 2020-11-03 Rigel Pharmaceuticals, Inc. TGF-β inhibitorC
EP3313420B1 (en) 2015-06-25 2024-03-13 The Children's Medical Center Corporation Methods and compositions relating to hematopoietic stem cell expansion, enrichment, and maintenance
EP3319968A1 (en) 2015-07-06 2018-05-16 Rodin Therapeutics, Inc. Heterobicyclic n-aminophenyl-amides as inhibitors of histone deacetylase
HUE057041T2 (hu) 2015-07-06 2022-04-28 Alkermes Inc Hiszton deacetiláz hetero-halogén gátlói
JP7080179B2 (ja) 2016-03-15 2022-06-03 ザ チルドレンズ メディカル センター コーポレーション 造血幹細胞の増大に関する方法および組成物
PT3470409T (pt) 2016-06-13 2020-05-11 Genfleet Therapeutics Shanghai Inc Composto de amida alfa e beta insaturada derivado de benzotriazol utilizado como inibidor de tgf-beta ri
KR102434226B1 (ko) * 2016-06-30 2022-08-19 한미약품 주식회사 Alk5 억제제로서의 신규 피라졸 유도체 및 이의 용도
ES2826748T3 (es) 2016-09-02 2021-05-19 Gilead Sciences Inc Derivados de 4,6-diamino-pirido[3,2-d]pirimidina como moduladores de receptores de tipo Toll
JP6746776B2 (ja) 2016-09-02 2020-08-26 ギリアード サイエンシーズ， インコーポレイテッド Ｔｏｌｌ様受容体調節剤化合物
CN108069955B (zh) * 2016-11-14 2021-04-06 江苏恒瑞医药股份有限公司 3-吡啶基-4-苯并噻唑基吡唑类衍生物、其制备方法及其在医药上的应用
JP2020500177A (ja) * 2016-11-14 2020-01-09 ジエンス ヘンルイ メデイシンカンパニー リミテッドＪｉａｎｇｓｕ Ｈｅｎｇｒｕｉ Ｍｅｄｉｃｉｎｅ Ｃｏ．，Ｌｔｄ． ３，４−ビピリジルピラゾール誘導体、およびその製造方法およびその医療応用
RS62959B1 (sr) 2017-01-11 2022-03-31 Alkermes Inc Biciklični inhibitori histon-deacetilaze
PT3664802T (pt) 2017-08-07 2022-05-24 Alkermes Inc Inibidores bicíclicos de histona-desacetilase
US11034669B2 (en) 2018-11-30 2021-06-15 Nuvation Bio Inc. Pyrrole and pyrazole compounds and methods of use thereof
EP3894401A2 (en) 2018-12-11 2021-10-20 Theravance Biopharma R&D IP, LLC Naphthyridine and quinoline derivatives useful as alk5 inhibitors
TWI827760B (zh) 2018-12-12 2024-01-01 加拿大商愛彼特生物製藥公司 經取代之芳基甲基脲類及雜芳基甲基脲類、其類似物及其使用方法
WO2020201362A2 (en) 2019-04-02 2020-10-08 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods of predicting and preventing cancer in patients having premalignant lesions
TW202212339A (zh) 2019-04-17 2022-04-01 美商基利科學股份有限公司 類鐸受體調節劑之固體形式
TWI751516B (zh) 2019-04-17 2022-01-01 美商基利科學股份有限公司 類鐸受體調節劑之固體形式
EP3956330A4 (en) 2019-04-18 2023-01-18 The Johns Hopkins University SUBSTITUTED 2-AMINO-PYRAZOLYL-[1,2,4]TRIAZOLO[1,5A]PYRIDINE DERIVATIVES AND THEIR USE
TW202115056A (zh) 2019-06-28 2021-04-16 美商基利科學股份有限公司 類鐸受體調節劑化合物的製備方法
CN114728941A (zh) 2019-11-22 2022-07-08 施万生物制药研发Ip有限责任公司 作为alk5抑制剂的经取代的1,5-萘啶或喹啉
CN114787145B (zh) * 2019-11-28 2024-03-26 阿戈麦布西班牙股份有限公司 作为转化生长因子-β受体I/ALK5抑制剂的苯甲酰胺衍生物
WO2021120890A1 (en) 2019-12-20 2021-06-24 Novartis Ag Pyrazolyl derivatives useful as anti-cancer agents
CN113620956B (zh) * 2020-05-06 2023-06-13 赛诺哈勃药业（成都）有限公司 转化生长因子受体拮抗剂、其制备方法和应用
CN112759592A (zh) * 2021-02-01 2021-05-07 无锡鸣鹭医药科技有限公司 一种6-碘[1,2,3]三唑并[1,5-a]吡啶的合成方法

Family Cites Families (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3940486A (en) * 1971-05-10 1976-02-24 Ciba-Geigy Corporation Imidazole derivatives in the treatment of pain
US4302464A (en) * 1980-10-16 1981-11-24 Pfizer Inc. Imidazolylpyridine therapeutic agents
US4686231A (en) * 1985-12-12 1987-08-11 Smithkline Beckman Corporation Inhibition of 5-lipoxygenase products
US4925857A (en) * 1989-03-22 1990-05-15 Sterling Drug Inc. Pyridinyl-1H-pyrazole-1-alkanamides as antiarrhythmic agents
JP2753659B2 (ja) * 1990-09-03 1998-05-20 株式会社大塚製薬工場 ピラゾール誘導体
US5916891A (en) * 1992-01-13 1999-06-29 Smithkline Beecham Corporation Pyrimidinyl imidazoles
IL104369A0 (en) * 1992-01-13 1993-05-13 Smithkline Beecham Corp Novel compounds and compositions
US5656644A (en) * 1994-07-20 1997-08-12 Smithkline Beecham Corporation Pyridyl imidazoles
DE4233713A1 (de) * 1992-10-07 1994-04-14 Bayer Ag Substituierte 4,5-Dihydro-1-pyrazolcarbonsäureanilide
US5593992A (en) * 1993-07-16 1997-01-14 Smithkline Beecham Corporation Compounds
US5593991A (en) * 1993-07-16 1997-01-14 Adams; Jerry L. Imidazole compounds, use and process of making
US5670527A (en) * 1993-07-16 1997-09-23 Smithkline Beecham Corporation Pyridyl imidazole compounds and compositions
US5486534A (en) * 1994-07-21 1996-01-23 G. D. Searle & Co. 3,4-substituted pyrazoles for the treatment of inflammation
GB9423460D0 (en) * 1994-11-21 1995-01-11 Merck Sharp & Dohme Therapeutic agents
JP3734180B2 (ja) * 1994-12-28 2006-01-11 エーザイ株式会社 新規ピラゾール誘導体
US5514505A (en) * 1995-05-15 1996-05-07 Xerox Corporation Method for obtaining improved image contrast in migration imaging members
US5593997A (en) * 1995-05-23 1997-01-14 Pfizer Inc. 4-aminopyrazolo(3-,4-D)pyrimidine and 4-aminopyrazolo-(3,4-D)pyridine tyrosine kinase inhibitors
US5739143A (en) * 1995-06-07 1998-04-14 Smithkline Beecham Corporation Imidazole compounds and compositions
US5658903A (en) * 1995-06-07 1997-08-19 Smithkline Beecham Corporation Imidazole compounds, compositions and use
WO1997001575A1 (fr) * 1995-06-29 1997-01-16 Fujisawa Pharmaceutical Co., Ltd. Substance wf16616, procede de production et utilisation
US5792778A (en) * 1995-08-10 1998-08-11 Merck & Co., Inc. 2-substituted aryl pyrroles, compositions containing such compounds and methods of use
US5837719A (en) * 1995-08-10 1998-11-17 Merck & Co., Inc. 2,5-substituted aryl pyrroles, compositions containing such compounds and methods of use
US5717100A (en) * 1995-10-06 1998-02-10 Merck & Co., Inc. Substituted imidazoles having anti-cancer and cytokine inhibitory activity
ZA9610687B (en) * 1995-12-22 1997-09-29 Smithkline Beecham Corp Novel synthesis.
ZA97175B (en) * 1996-01-11 1997-11-04 Smithkline Beecham Corp Novel substituted imidazole compounds.
JP2000503302A (ja) * 1996-01-11 2000-03-21 スミスクライン・ビーチャム・コーポレイション 新規置換イミダゾール化合物
US5854265A (en) * 1996-04-03 1998-12-29 Merck & Co., Inc. Biheteroaryl inhibitors of farnesyl-protein transferase
US5883105A (en) * 1996-04-03 1999-03-16 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
US5939557A (en) * 1996-04-03 1999-08-17 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
US5880140A (en) * 1996-04-03 1999-03-09 Merck & Co., Inc. Biheteroaryl inhibitors of farnesyl-protein transferase
US5872136A (en) * 1996-04-03 1999-02-16 Merck & Co., Inc. Arylheteroaryl inhibitors of farnesyl-protein transferase
JP3418624B2 (ja) * 1996-06-10 2003-06-23 メルク エンド カンパニー インコーポレーテッド サイトカイン阻害活性を有する置換イミダゾール類
US5854264A (en) * 1996-07-24 1998-12-29 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
WO1998021199A2 (en) * 1996-11-12 1998-05-22 Novartis Ag Pyrazole derivatives useful as herbicides
US5939439A (en) * 1996-12-30 1999-08-17 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
AU7138298A (en) * 1997-04-24 1998-11-13 Ortho-Mcneil Corporation, Inc. Substituted imidazoles useful in the treatment of inflammatory diseases
EP0983260A2 (en) * 1997-05-22 2000-03-08 G.D. Searle & Co. 3(5)-HETEROARYL SUBSTITUTED PYRAZOLES AS p38 KINASE INHIBITORS
EP1341772A2 (en) * 2000-12-11 2003-09-10 E. I. du Pont de Nemours and Company Quinazolinones and pyridinylpyrimidinones for controlling invertebrate pests
JP2004521901A (ja) * 2001-02-02 2004-07-22 グラクソ　グループ　リミテッド Ｔｇｆ阻害剤としてのピラゾール
US20040087623A1 (en) * 2001-02-02 2004-05-06 Gellibert Francoise Jeanne Pyrazole derivatives against tgf overexpression
GB0102672D0 (en) * 2001-02-02 2001-03-21 Glaxo Group Ltd Compounds
DE10113000A1 (de) * 2001-03-17 2002-09-19 Bayerische Motoren Werke Ag System aus Verbrennungsmotor und Brennstoffzelle
WO2002088107A1 (en) * 2001-04-26 2002-11-07 Eisai Co., Ltd. Nitrogenous fused-ring compound having pyrazolyl group as substituent and medicinal composition thereof
SI1397364T1 (sl) * 2001-05-24 2007-12-31 Lilly Co Eli Novi pirolni derivati kot farmacevtske uäśinkovine
ES2319972T3 (es) * 2001-10-15 2009-05-18 E.I. Du Pont De Nemours And Company Iminobenzoxazinas, iminobenzotiazinas e iminoquinazolinas para controlar plagas de invertebrados.
AR040726A1 (es) * 2002-07-31 2005-04-20 Smithkline Beecham Corp Compuesto de 2- fenilpiridin-4-il-heterociclico, composicion farmaceutica que lo comprende y su uso para la fabricacion de un medicamento
GB0217786D0 (en) * 2002-07-31 2002-09-11 Glaxo Group Ltd Compounds
MXPA05002376A (es) * 2002-09-18 2005-05-23 Pfizer Prod Inc Nuevos compuestos de pirazol como inhibidores del factor de crecimiento transformante (tgf).
AU2003268155A1 (en) * 2002-09-19 2004-04-08 Eli Lilly And Company Methods of inhibiting tgf beta with substituted pyrazoles
GB0313915D0 (en) * 2003-06-16 2003-07-23 Smithkline Beecham Corp Compounds

Also Published As

Publication number Publication date
US20060264440A1 (en) 2006-11-23
KR20050101547A (ko) 2005-10-24
UA82223C2 (uk) 2008-03-25
EA010161B1 (ru) 2008-06-30
NO20054200L (no) 2005-10-14
WO2004072033A2 (en) 2004-08-26
NZ542289A (en) 2009-03-31
EP1596656A2 (en) 2005-11-23
BRPI0407454A (pt) 2006-01-24
CN1770980A (zh) 2006-05-10
EA200501274A1 (ru) 2006-02-24
PL378072A1 (pl) 2006-02-20
MXPA05008524A (es) 2005-10-20
AU2004210855A1 (en) 2004-08-26
NO20054200D0 (no) 2005-09-09
EP1596656A4 (en) 2006-10-18
IS7966A (is) 2005-07-29
CL2004000234A1 (es) 2005-04-15
ZA200506408B (en) 2006-05-31
JP2006517592A (ja) 2006-07-27
WO2004072033A3 (en) 2005-03-17
AR043184A1 (es) 2005-07-20
CA2514382A1 (en) 2004-08-26
GEP20084391B (en) 2008-06-10

Similar Documents

Publication Publication Date Title
MXPA05008524A (es) Pirazoles y metodos de elaboracion y uso de los mismos.
RS20050199A (en) Imidazolopyridines and methods of making and using the same
RS95904A (en) Tri -substituted heteroaryls and methods for making and using the same
TW200621752A (en) Pyrimidinylpyrazoles and methods of making and using the same
TW200621753A (en) Pyrimidinylimidazoles and methods of making and using the same
MXPA05002443A (es) Pirazolopiridinas y metodos para elaboracion y uso de las mismas.
HK1083838A1 (en) A2a adenosine receptor antagonists
JO2311B1 (en) Alkyl inhibitors Ariel phosphodiesterase-4
MXPA06000716A (es) Derivados de quinolina y quinazolina que tienen afinidad hacia receptores del tipo 5ht1.
AU2003281213A1 (en) 1-amido-4-phenyl-4-benzyloxymethyl-piperidine derivatives and related compounds as neurokinin-1(nk-1) antagonists for the treatment of emesis, depression, anxiety and cough
MY135841A (en) Novel benzodioxoles
RS20050810A (en) 5,7-diaminopyrazolo(4,3-d)pyrimidines useful in the treatment of hypertension
GB0325956D0 (en) Novel compounds
WO2004069152A3 (en) Δ4,5 glycuronidase and uses thereof
WO2005075450A3 (en) Spiro-benzodioxoles and their use as cb1 antagonists
DE60324544D1 (de) Muskarin antagonisten
ZA200404752B (en) 6-aminomorphinane derivatives method for the production and use thereof
GB0114185D0 (en) Compounds
MXPA04004477A (es) Antagonistas del neuropeptido neuroquinina-1(nk1).
MXPA02009549A (es) Imidazopiridinas triciclicas.
MXPA04004981A (es) Derivados de piperazina para uso como antagonistas del receptor ccr-3 en tratamiento de asma.
SI1377574T1 (sr)
MXPA02012400A (es) Heterociclos hetaril-substituidos.
MXPA04004980A (es) Antagonistas del receptor ccr-3.
MXPA04001977A (es) Antagonistas v de receptor ccr-3.